Autopsy report · NCT05561530

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

“Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 57 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Aligos Therapeutics

Sponsor type

Industry

Conditions

Chronic Hepatitis B

Interventions

ALG-125755; Placebo

Participants

57

Sites

4

Countries

Bulgaria, Moldova, New Zealand, Romania

Trials that died the same way

• A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
  “Dose limiting toxicity at the lowest planned dose level.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.